News
After US Clearance, Mabwell Secures Chinese Approval for IBD Antibody Trials
Mabwell said the NMPA has also accepted clinical trial applications for its antibody drug candidate, 9MW5211, in multiple sclerosis.
ADDRESS: Street, City, Country
PHONE: +(123) 456 789
E-MAIL: your-email@mail.com
Mabwell said the NMPA has also accepted clinical trial applications for its antibody drug candidate, 9MW5211, in multiple sclerosis.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Email Us: support@healthxploreindia.com
Contact: +91 8447496924
HealthXploreIndia @2026. All Rights Reserved.
